T. Rowe Price Associates
SGMT icon

T. Rowe Price Associates’s Sagimet Biosciences SGMT Stock Holding History

T. Rowe Price Associates’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,918
Closed -$43K – 3139
2025
Q1 		$43K Buy
+12,918
New +$54.2K ﹤0.01% 2947
2024
Q3 		– Sell
-10,069
Closed -$35K – 3024
2024
Q2 		$35K Sell
10,069
-6,636
-40% -$30.4K ﹤0.01% 2888
2024
Q1 		$91K Buy
+16,705
New +$120K ﹤0.01% 2798

Other funds holding SGMT

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.23B AUM 15% 1-Year Est. Return

T. Rowe Price Associates's SGMT Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Sagimet Biosciences (SGMT) in Q2 2025, closing a stake of 12,918 shares — an estimated $43K sold.

T. Rowe Price Associates first reported a position in SGMT in Q1 2024 and held it in 3 quarters. The position peaked at $91K in Q1 2024. 67 funds tracked by Wall St. Rank hold SGMT as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Sagimet Biosciences position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 12,918 Sagimet Biosciences shares in Q2 2025, an estimated $43K.
  • T. Rowe Price Associates first reported a position in Sagimet Biosciences in Q1 2024 and held it in 3 quarters.
  • T. Rowe Price Associates's Sagimet Biosciences position peaked at $91K in Q1 2024.
  • 67 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.